Skip to main content

The Jackson Laboratory

Home

Recent Searches

Share this Post

Share on facebook
Share on twitter
Share on linkedin
Share on email

The Jackson Laboratory's EU Symposium

Home
Advances and Applications of Humanized In Vivo Models in Preclinical Drug Development
In Vivo Evaluation of Bispecific T-Cell Engager Efficacy and Safety

In Vivo Evaluation of Bispecific T-Cell Engager Efficacy and Safety

Published Date March 24, 2023

Loading, please wait

Error - something went wrong!

Ready to discuss your project needs with our experts?

Thank you, we will be in touch soon!

Previous Article

Evidence-based selection of the starting dose in first-in-human clinical trials using humanized mouse models

The dose selection for first-in-human (FIH) clinical trials relies on data obtained by a combination of in vitro and in vivo studies designed to evaluate the efficacy, toxicity, and stability of...
Next Flipbook

In vivo Preclinical Efficacy & Safety of CAR-T, -NK, and -Myeloid Based Therapies

Other content in this Stream

11 months ago
HuPK Highlights for EU Symposium

Read Flipbook
11 months ago
Humanized Mice Highlights for EU Symposium

Read Flipbook
11 months ago
CRS Highlights for EU Symposium

Read Flipbook
about 1 year ago
FcRn model platform

The FcRn platform from The Jackson Laboratory mimics specific aspects of the human IgG physiology providing the ideal model platform to assess the pharmacokinetics (PK) of therapeutic antibody candida

Watch Video
over 3 years ago
Use of FcRn Transgenic mice for drug discovery of therapeutic antibodies with Roche's Michael Otteneder, PhD

Watch Video
about 2 years ago
Evidence-based selection of the starting dose in first-in-human clinical trials using humanized mouse models

The dose selection for first-in-human (FIH) clinical trials relies on data obtained by a combination of in vitro and in vivo studies designed to evaluate the efficacy, toxicity, and stability of...

Learn More
over 1 year ago
In vivo Preclinical Efficacy & Safety of CAR-T, -NK, and -Myeloid Based Therapies

Read Flipbook
about 2 years ago
Achieving Relevant Preclinical Characterization of CAR T Cell Therapies

This whitepaper examines the constraints and challenges inherent in each CAR T study type and how to overcome them with in vivo studies using fully humanized mouse models.

Read Flipbook
about 2 years ago
CRS Studies for CAR T Cell Therapy

Review JAX’s CRS evaluation capabilities and see how a CRS study can help move your CAR T therapeutic into the clinic faster, safer, and more confidently.

Read Flipbook
over 2 years ago
The Humanized FcRn Platform: An Essential Tool for Preclinical PK Assessment of Therapeutic Antibody Candidates

Greg Christianson, Study Director, In Vivo Services, The Jackson Laboratory speaks about the use of human FcRn transgenic mouse models to select antibody therapeutic candidates with optimum pharmacoki

Watch Video
over 3 years ago
Targeting Natural Killer Cell Activity with Humanized NSG IL-15 Mouse Model

The NEW cord blood CD34+ HSC humanized NSG-IL15 mouse enables efficacy research for compounds targeting human natural killer (NK) cell activity including antibody-dependent cellular cytotoxicity.

Read Flipbook
over 3 years ago
JAX Guide: Assessing Antibody Pharmacokinetics Using the JAX FcRn Platform

Read Flipbook
about 2 months ago
Humanized NSG Mouse Models

CD34 and PBMC humanized NSG mice are powerful preclinical models for studying the actions of immuno-modulators, either alone or in combination with other treatments.

Read Flipbook

Return to Home

© The Jackson Laboratory